Show simple item record

dc.contributor.authorKolls, Jay K.
dc.contributor.authorSzabo, Gyongyi
dc.date2022-08-11T08:08:32.000
dc.date.accessioned2022-08-23T15:58:08Z
dc.date.available2022-08-23T15:58:08Z
dc.date.issued2015-01-01
dc.date.submitted2015-05-29
dc.identifier.citationJ Clin Invest. 2015 Jan;125(1):97-8. doi: 10.1172/JCI79424. Epub 2014 Dec 15. <a href="http://dx.doi.org/10.1172/JCI79424">Link to article on publisher's site</a>
dc.identifier.issn0021-9738 (Linking)
dc.identifier.doi10.1172/JCI79424
dc.identifier.pmid25500881
dc.identifier.urihttp://hdl.handle.net/20.500.14038/30365
dc.description.abstractHepatitis C virus (HCV) is a leading cause of chronic liver disease, and efforts to develop therapeutic vaccine strategies have been limited by immune escape due to HCV variants that are resistant to current vaccines or HCV variants that rapidly acquire new resistance-conferring mutations. Recently, the crystal structure of the viral envelope protein E2 region was resolved as well as how E2 docks to the host CD81 protein; therefore, antibodies that block this interaction should prevent viral entry into host cells. In this issue of the JCI, Bailey and colleagues show that immune escape of HCV can occur by naturally occurring polymorphisms in E2 that are distinct from those at mapped sites of antibody binding. These data reveal alternative mechanisms of resistance that need to be considered in both natural viral escape as well as in rationale vaccine design against HCV.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=25500881&dopt=Abstract">Link to Article in PubMed</a>
dc.rightsPublisher PDF posted as allowed by the publisher's author rights policy at http://static.the-jci.org/content_assets/admin/forms/jcicopyright.pdf.
dc.subjectAntibodies, Neutralizing
dc.subjectHepacivirus
dc.subjectHumans
dc.subject*Neutralization Tests
dc.subject*Polymorphism, Genetic
dc.subjectDigestive System Diseases
dc.subjectGastroenterology
dc.subjectGenetics
dc.subjectImmunity
dc.subjectImmunoprophylaxis and Therapy
dc.titleThe genetics of hepatitis C virus underlie its ability to escape humoral immunity
dc.typeJournal Article
dc.source.journaltitleThe Journal of clinical investigation
dc.source.volume125
dc.source.issue1
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1635&amp;context=faculty_pubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/636
dc.identifier.contextkey7158515
refterms.dateFOA2022-08-23T15:58:09Z
html.description.abstract<p>Hepatitis C virus (HCV) is a leading cause of chronic liver disease, and efforts to develop therapeutic vaccine strategies have been limited by immune escape due to HCV variants that are resistant to current vaccines or HCV variants that rapidly acquire new resistance-conferring mutations. Recently, the crystal structure of the viral envelope protein E2 region was resolved as well as how E2 docks to the host CD81 protein; therefore, antibodies that block this interaction should prevent viral entry into host cells. In this issue of the JCI, Bailey and colleagues show that immune escape of HCV can occur by naturally occurring polymorphisms in E2 that are distinct from those at mapped sites of antibody binding. These data reveal alternative mechanisms of resistance that need to be considered in both natural viral escape as well as in rationale vaccine design against HCV.</p>
dc.identifier.submissionpathfaculty_pubs/636
dc.contributor.departmentDepartment of Medicine, Division of Gastroenterology
dc.source.pages97-8


Files in this item

Thumbnail
Name:
JCI79424.pdf
Size:
198.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record